使用基于高通量和定量发光的报告基因分析评估 DNA 双链断裂修复活性
2024年6月14日
2.7K 次观看
我们提出了使用一套基于发光的染色体外报告基因底物评估细胞中双链断裂修复途径熟练程度的方案。
Artios 正在开发针对 DNA 损伤反应的新型抗癌药物。为了实现这一点，我们开发了一系列新的检测方法来测量细胞 DNA 修复活性。这些检测对我们的项目产生了重大影响，导致临床阶段的资产在医疗需求高度未满足的患者中进行测试。
准确测量靶向细胞活性对于推进新型靶向治疗至关重要。无论是需要高通量、稳定的信噪比、快速周转，还是理想情况下需要到不同生物系统的便携性，生成具有所需特性的 DNA 修复因子分析一直是一项挑战。我们开发了一套稳健、定量和可滴定的基于发光的报告基因分析，用于测量四种主要双链断裂修复途径、同源重组、非同源末端连接、微同源介导的末端连接和单链退火的熟练程度。
这些报告基因检测经验证为读出通路依赖性修复，对药理学调节敏感，并且周转时间短。我们开发的修复底物是染色体外的，因此它们可以瞬时转染到目标模型中，并轻松放大到高通量形式中。我们相信我们的检测系统在实现 DDR 药物发现方面发挥着重要作用，而且在更广泛地促进我们对 DDR 生物学的理解方面也发挥着重要作用。
在这方面，我们希望这些方法有助于加速新药物靶点的识别和起诉，从而为医疗需求未得到满足的癌症等疾病提供药物。
概览
本文介绍了使用基于发光的染色体外报告基质来评估细胞中双链断裂修复通路能力的协议。开发的检测对于理解DNA损伤反应和促进肿瘤学中的药物发现至关重要。
关键研究组成部分
科学领域
- DNA损伤反应
- 细胞修复机制
- 肿瘤学药物发现
背景
- DNA中的双链断裂是需要有效修复的关键损伤。
- 理解修复通路对于开发靶向癌症疗法至关重要。
- 现有的DNA修复活动测量检测在通量和敏感性方面存在限制。
- 新的检测可以通过准确测量细胞活性来增强药物发现努力。
研究目的
- 开发用于测量主要双链断裂修复通路能力的稳健检测。
- 促进癌症治疗中新药靶点的识别。
- 提高对DNA损伤反应生物学的理解。
所用方法
- 开发四种修复通路的基于发光的报告基质检测。
- 将染色体外基质暂时转染到细胞模型中。
- 测量发光信号以评估修复能力。
- 验证检测对药理调节的敏感性。
主要结果
- 检测显示了通路依赖的修复活性。
- 定量测量显示对药物调节的敏感性。
- 检测结果实现了快速周转时间。
- 检测可以扩展用于高通量筛选。
结论
- 开发的检测是癌症药物发现的有价值工具。
- 它们增强了对DNA修复机制的理解。
- 这些方法可以加速新治疗靶点的识别。
常见问题
什么是双链断裂？
双链断裂是严重的DNA损伤形式，如果不修复会导致基因组不稳定。
所开发的检测如何工作？
这些检测使用基于发光的报告基质来测量细胞中DNA修复通路的效率。
为什么测量DNA修复很重要？
测量DNA修复对于理解癌症生物学和开发有效疗法至关重要。
评估哪些类型的DNA修复通路？
这些检测评估同源重组、非同源末端连接、微同源性介导的末端连接和单链退火。
这些检测可以用于高通量筛选吗？
是的，这些检测被设计为可以扩展用于高通量应用。
染色体外基质有什么意义？
染色体外基质允许在不同生物系统中实现短暂表达和更容易的扩展。
Executive Industry Relevance
Quantitative luminescence-based reporter assays for DNA double strand break repair enable high-throughput, pathway-specific measurement of cellular DNA repair activity, directly supporting target validation and mechanistic de-risking in oncology drug discovery. These assays provide rapid, reproducible, and scalable outputs essential for advancing DNA damage response (DDR) therapeutics. Their integration into discovery pipelines enhances predictive confidence and portfolio triage for DDR-targeted assets.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of DDR pathway activity for functional target validation.
- Supports mechanistic de-risking by distinguishing pathway-specific repair proficiency.
- Facilitates predictive confidence in target engagement and biological relevance.
- Accelerates identification and prioritization of novel DDR drug targets.
Screening & Assay Development
- Provides validated, quantitative readouts for robust assay standardization.
- Delivers high-throughput, scalable formats suitable for compound screening.
- Ensures reproducibility and titratability across diverse biological systems.
- Enables reliable evaluation of pharmacological modulation of DNA repair pathways.
Translational & Preclinical Research
- Aligns pathway-specific repair measurements with disease-relevant DDR biology.
- Supports continuity from discovery through preclinical validation of DDR targets.
- Informs risk-adjusted advancement decisions for DDR-focused portfolios.
- Provides mechanistic insights to guide translational biomarker strategies.
Pipeline & Workflow Integration
These assays position within the discovery continuum from early target validation through lead identification and preclinical evaluation of DDR-targeted therapeutics.
- Discovery Biology: Supports hypothesis testing and pathway clarification for DDR mechanisms.
- Screening: Delivers assay readiness, reproducibility, and quantitative outputs for compound evaluation.
- Analytics: Provides sensitive luminescence measurements to compare repair activity across conditions.
- Translational Research: Enables alignment of cellular repair proficiency with disease models when relevant.
- Enterprise Reuse: Offers a portable, scalable platform adaptable to multiple cell systems and discovery programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in DDR target validation.
- Operational Value: Standardizes and accelerates assay workflows with high-throughput scalability.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust biological readouts.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of DDR-targeted assets.
Implementation Considerations
- Requires expertise in molecular biology and luminescence assay design.
- Needs access to luminescence plate readers and standard cell culture infrastructure.
- Demands cross-team standardization for assay reproducibility and data comparability.
- Adaptable to various cell models via transient transfection of extrachromosomal substrates.
- Dependent on validated controls to distinguish pathway-specific repair activity.
Biopharma FAQs
Why does null hypothesis testing matter for NanoLuc repair assays?
Null hypothesis testing in NanoLuc-based repair assays ensures that observed luminescence changes are statistically significant and attributable to specific DNA repair pathway activity, not random variation. This rigor is essential for target validation and reliable go/no-go decisions in DDR drug discovery. It underpins confidence in mechanistic conclusions drawn from assay outputs.
How does independent variable isolation fit the NanoLuc DDR workflow?
Isolating variables such as compound treatment or genetic perturbation in the NanoLuc DDR workflow allows precise attribution of changes in repair activity to specific interventions. This supports mechanistic de-risking and informs structure-activity relationship studies during early discovery. It also enables clear interpretation of pathway-specific modulation.
What do quantitative NanoLuc luminescence measurements enable in screening?
Quantitative NanoLuc luminescence measurements provide sensitive, reproducible readouts of DNA repair proficiency, enabling robust comparison of compound effects across conditions. This facilitates high-throughput screening and prioritization of hits with desired DDR pathway modulation. It also supports data-driven advancement decisions in lead identification.
Why are replication requirements critical for cross-functional DDR assay use?
Replication ensures that NanoLuc DDR assay results are reproducible and reliable across different teams, cell models, and experimental runs. This is vital for cross-functional collaboration, assay transferability, and enterprise-wide data confidence. Consistent replication underpins portfolio-level decision-making and risk management.
What statistical analysis is required before implementing NanoLuc DDR assays?
Statistical analysis of NanoLuc DDR assay data must include controls for signal normalization, assessment of variance, and significance testing to validate pathway-specific effects. These analyses are necessary to confirm assay robustness and support actionable conclusions in drug discovery workflows. Proper statistical rigor ensures assay outputs are suitable for pipeline integration.
